thiazolyl blue has been researched along with imatinib mesylate in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corey, SJ; Dai, Y; Dent, P; Grant, S; Rahmani, M | 1 |
| Brabant, G; Jakubcakova, V; Kant, S; Kremenevskaja, N; Rao, AS; Resch, J; von Wasielewski, R | 1 |
| Plattner, R; Sims, JT | 1 |
| Facoetti, A; Mazzini, G; Nano, R; Ranza, E | 1 |
| Bang, S; Chung, HW; Lim, JB; Park, SW; Song, SY; Wen, J | 1 |
| Ashby, CR; Chen, A; Chen, X; Chen, ZS; Hopper-Borge, E; Kuang, YH; Lei, Y; Ouyang, J; Shen, T; Tiwari, AK; Zhou, Y | 1 |
| Igishi, T; Kodani, M; Matsumoto, S; Matsunami, K; Morita, M; Nakazaki, H; Shigeoka, Y; Shimizu, E; Sumikawa, T; Suyama, H; Takeda, K; Ueda, Y | 1 |
| Gong, YP; Guo, Y; Lin, J; Shi, R | 1 |
8 other study(ies) available for thiazolyl blue and imatinib mesylate
| Article | Year |
|---|---|
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Topics: Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Protein; bcl-X Protein; Benzamides; Blotting, Western; Cell Line; Cell Line, Tumor; Coloring Agents; Cytochromes c; DNA-Binding Proteins; DNA, Complementary; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flavoproteins; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Membrane Potentials; Membrane Proteins; Milk Proteins; Mitochondria; Mutation; Piperazines; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; src-Family Kinases; STAT5 Transcription Factor; Tetrazolium Salts; Thiazoles; Trans-Activators; Transfection; Up-Regulation | 2004 |
Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; beta Catenin; Blotting, Western; Carcinoma; Caspase 3; Caspase 7; Caspases; Cell Proliferation; Collagen; Drug Combinations; Fluorescent Antibody Technique; Genes, Reporter; Humans; Imatinib Mesylate; Immunoprecipitation; Laminin; Luciferases; Microscopy, Confocal; Oligonucleotide Array Sequence Analysis; Piperazines; Proteoglycans; Pyrimidines; Signal Transduction; Tetrazolium Salts; Thiazoles; Thymidine; Thyroid Neoplasms; Transfection; Tumor Cells, Cultured | 2006 |
MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Melanoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tetrazolium Salts; Thiazoles | 2009 |
In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation.
Topics: Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Size; Cell Survival; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Flow Cytometry; Glioblastoma; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tetrazolium Salts; Thiazoles | 2010 |
Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro.
Topics: Analysis of Variance; Apoptosis; Benzamides; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Formazans; Genes, ras; Humans; Imatinib Mesylate; Mutation; Pancreatic Neoplasms; Phospholipase C gamma; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, Platelet-Derived Growth Factor beta; Tetrazolium Salts; Thiazoles; Time Factors | 2009 |
Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).
Topics: Antineoplastic Agents; Benzamides; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Models, Chemical; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Piperazines; Pyrimidines; Tetrazolium Salts; Thiazoles | 2009 |
Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Topics: Anthracyclines; Benzamides; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Imatinib Mesylate; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Small Cell Lung Carcinoma; Tetrazolium Salts; Thiazoles | 2010 |
The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Butadienes; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Humans; Imatinib Mesylate; Indicators and Reagents; K562 Cells; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Nitriles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Pyrimidines; Real-Time Polymerase Chain Reaction; src-Family Kinases; STAT5 Transcription Factor; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases | 2014 |